GSK, Garmin Exceed Q2 Forecasts and Raise Guidance

GSK exceeded analyst expectations in Q2 2025, reporting earnings of 46.5 pence per share and 6% turnover growth to nearly 8 billion pounds, driven by strong specialty medicines and vaccines sales. The company now expects annual sales and profit growth toward the top end of its forecast range, despite facing potential U.S. pharmaceutical tariffs, increased competition, and regulatory and pricing pressures. GSK has set a long-term target of over 40 billion pounds in annual sales by 2031 and continues to invest in expanding its product pipeline. Meanwhile, Garmin also reported strong second-quarter results, with adjusted earnings of $2.17 per share on $1.81 billion in sales, leading to upgraded full-year guidance and a rise in its stock price. Garmin's growth was supported by robust demand for fitness and outdoor technology products. The positive results from both companies underscore resilience in their respective sectors amid ongoing economic and market challenges.